



Cymat Technologies Ltd.
Management's Discussion and Analysis (“MD&A”)
As at October 31, 2015

December 14, 2015

The following discussion and analysis of Cymat Technologies Ltd. (“Cymat” or the “Company”) financial condition and results of operations should be read in conjunction with Cymat’s unaudited interim financial statements for the three and six month periods ended October 31, 2015, and the audited financial statements for the year ended April 30, 2015, and the associated notes to the financial statements.

The Company prepares its unaudited interim financial statements in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board [“IASB”]. All financial information contained in this MD&A and in the unaudited interim financial statements has been prepared in accordance with IAS 34, Interim Financial Reporting.

This MD&A is dated December 14, 2015 and all amounts herein are denominated in Canadian dollars, unless otherwise stated.

The information below contains certain forward-looking statements that reflect the current view of Cymat with respect to future events and financial performance. Wherever used, the words “may”, “will”, “anticipate”, “intend”, “expect”, “plan”, “believe”, and similar expressions identify forward-looking statements. Any such forward-looking statements are subject to risks and uncertainties, and the Company's actual results of operations could differ materially from historical results or current expectations. The Company will review the forward-looking information in the preparation of the MD&A on a quarterly basis and, where appropriate, provide updated forward-looking statements based on the most current view of Cymat.

1. Company Overview and Business of Company

Cymat was incorporated on June 13, 2006 under the Business Corporations Act (Ontario) and is the successor to Duntroon Energy (formerly Cymat Corp.) which was incorporated on June 30, 1998 under the Business Corporations Act (Ontario).

Cymat develops innovative materials for industry. The Company has worldwide rights, through patents and licenses, to produce Stabilized Aluminum Foam (“SAF”). This ultra-light metallic foam is produced using a proprietary, versatile process in which gas is bubbled into molten-alloyed aluminum containing a dispersion of fine ceramic particles to create foam that is then cast into either flat panels or near-net shapes. The result is a material, which is recyclable, with a wide array of features including very low density, mechanical energy absorption, thermal and acoustic insulation, time and temperature insensitivity and has a relatively low cost of production. The technology is focused on producing products for 3 major markets: automotive, architecture and blast mitigation industries. Cymat markets architectural material

under the trademark, “Alusion™” and automotive and blast mitigation products under the “SmartMetal™” trademark.

2. Summary of Operating Results

Select financial information for the three and six month periods ended October 31, 2015 and October 31, 2014:

	Three Months Ended October 31		Six Months Ended October 31	
	2015	2014	2015	2014
	(\$)	(\$)	(\$)	(\$)
Interim Statements of Operations				
Revenue	243,785	624,669	500,933	771,409
Plant operating expenses	351,363	364,348	681,754	499,677
Research and material testing expense	1,284	1,606	2,568	3,211
Selling, general and administrative expenses	266,694	342,987	540,619	555,227
Loss from operations	(375,556)	(84,272)	(724,008)	(286,706)
Net loss	(504,895)	(175,016)	(980,156)	(413,420)
Interim Statements of Cash Flows				
Cash used in operating activities	(88,275)	(343,602)	(295,430)	(750,723)

3. Results of Operations

Comparison of the Three Months Ended October 31, 2015 and October 31, 2014

Revenue

Revenue for the quarter ended October 31, 2015 was approximately \$244,000, a decrease of \$381,000, or 61%, from revenue for the quarter ended October 31, 2014, of \$625,000. Alusion™ revenue in the second quarter of the preceding fiscal year included \$436,000 from the Prada Museum installation as compared to major project architectural revenue from the Caxia Forum of \$82,000 in the current quarter.

Cymat recognizes product revenue when rights and obligations to the product are transferred to Cymat’s customers. Normally this transfer occurs when the products depart the Company warehouse; however this transfer can also occur upon the product arrival at a designated shipping location.

Plant Operating Expenses

Plant operating expenses for the quarter ended October 31, 2015 were approximately \$351,000, a decrease of \$13,000 as compared to the same expenses of \$365,000 for the quarter ended October 31, 2014.

Plant operating expenses include the direct operating expenses of labour, material, consumables, maintenance, freight and changes in inventory as well as manufacturing overhead costs. These direct operating expenses were approximately \$264,000 for the second quarter of fiscal 2016, as compared to \$304,000 for the second quarter of fiscal 2015. The current quarter expenses reflect the conversion of older panel inventory into raw material used for panel production in the current quarter. The comparative quarter for last fiscal year experienced an inventorying of production costs related to panels produced for the Prada Museum order and shipped subsequent to period end.

Plant operating expenses also includes factory overhead costs such as rent and utilities. These expenses totalled approximately \$73,000 for the second quarter of fiscal 2016 as compared to similar expenses of \$47,000 for the same period of fiscal 2015. Increased rental rates for the current period combined with the recording of a property tax refund in the last fiscal year accounted for the difference in expenses.

Plant operating expenses also include depreciation and amortization expense of approximately \$15,000 for the three months ended October 31, 2015 and \$13,000 for the same period ended October 31, 2014.

Research and Material Testing Expenses

Research and material testing expenses consisted of depreciation expenses on lab and testing equipment of \$1,000 for the second quarter of fiscal 2016 and \$2,000 for the second fiscal quarter of 2015.

Selling, General and Administrative Expenses (“SG&A”)

SG&A expenses for the three months ended October 31, 2015 were approximately \$267,000, as compared to an expense of \$343,000 for the same three months ended October 31, 2014. Favourable variances included decreased stock-based compensation expenses (\$38,000), decreased professional fees (\$17,000) and decreased consulting fees (\$14,000).

SG&A expenses also include depreciation and amortization in the approximate amounts of \$1,000 for each of the second quarters of fiscal 2016 and 2015.

Interest and Financing Expense

Interest and financing expense for the three months ended October 31, 2015, includes cash-based amounts of approximately \$79,000 which consisted of \$12,000 in royalty-based financing fees payable on the promissory notes (including \$5,000 payable to a related party), \$300 interest on the repayable government contributions liability and \$67,000 in cash-based interest on the convertible debentures (including \$7,000 payable to a related party). The expense for the quarter also includes a non-cash-based amount of \$49,000 pertaining to the accretion of interest on the carrying value of the loan component of the convertible debt.

Interest and financing expense for the three months ended October 31, 2014, includes cash-based amounts of approximately \$79,000 which consisted of \$32,000 in interest and royalty-based financing fees payable on the promissory notes (including \$12,000 payable to a related party), \$1,000 interest on the repayable government contributions liability and \$46,000 in cash-based interest on the convertible debentures (including \$7,000 payable to a related party). The expense for the quarter also includes a non-cash-based

amount of \$26,000 pertaining to the accretion of interest on the carrying value of the loan component of the convertible debt.

Net Income (Loss)

A net loss of \$505,000 was recorded for the second quarter of fiscal 2016, compared to a net loss of \$175,000 for the second quarter of fiscal 2015.

The net loss for the second quarter of fiscal 2016 includes the non-cash items of depreciation and amortization of approximately \$17,000 (fiscal 2015 – \$16,000), share-based compensation/consulting expenses of approximately \$26,000 (fiscal 2015 – \$61,000) and non-cash interest of \$49,000 (fiscal 2015 – \$26,000).

Comparison of the Six Months Ended October 31, 2015 and October 31, 2014

Revenue

Revenue for the six months ended October 31, 2015 was approximately \$501,000, a decrease of \$270,000, or 35%, from revenue for the period ended October 31, 2014, of \$771,000. Alusion™ revenue in the first half of the preceding fiscal year included \$436,000 from the Prada Museum installation as compared to major project architectural revenue from the Caxia Forum of \$82,000 and \$162,000 from follow-on orders for the Mallorca Convention Center in the current quarter.

Cymat recognizes product revenue when rights and obligations to the product are transferred to Cymat's customers. Normally this transfer occurs when the products depart the Company warehouse; however this transfer can also occur upon the product arrival at a designated shipping location.

Plant Operating Expenses

Plant operating expenses for the six months ended October 31, 2015 were approximately \$682,000, an increase of \$182,000 as compared to the same expenses of \$500,000 for the six months ended October 31, 2014.

Plant operating expenses include the direct operating expenses of labour, material, consumables, maintenance, freight and changes in inventory as well as manufacturing overhead costs. These direct operating expenses were approximately \$503,000 for the first half of fiscal 2016, as compared to \$358,000 for the first half of fiscal 2015. The current period expenses reflect the conversion of older panel inventory into raw material used for panel production in the current period. The comparative period for last fiscal year experienced an inventorying of production costs related to panels produced for the Prada Museum order and shipped subsequent to period end.

Plant operating expenses also includes factory overhead costs such as rent and utilities. These expenses totalled approximately \$149,000 for the first half of fiscal 2016 as compared to similar expenses of \$115,000 for the same period of fiscal 2015. Increased rental rates for the current period combined with the recording of a property tax refund in the last fiscal year accounted for the difference in expenses.

Plant operating expenses also include depreciation and amortization expense of approximately \$29,000 for the six months ended October 31, 2015 and \$27,000 for the same period ended October 31, 2014.

Research and Material Testing Expenses

Research and material testing expenses consisted of depreciation expenses on lab and testing equipment of \$3,000 for the first halves of fiscal 2016 and fiscal 2015.

Selling, General and Administrative Expenses (“SG&A”)

SG&A expenses for the six months ended October 31, 2015 were approximately \$541,000, as compared to an expense of \$555,000 for the same six months ended October 31, 2014. A favourable variance of \$17,000 for legal and audit fees was the primary factor in the expense decline.

SG&A expenses also include depreciation and amortization in the approximate amounts of \$2,000 and \$3,000, respectively, for each of the first halves of fiscal 2016 and 2015.

Interest and Financing Expense

Interest and financing expense for the six months ended October 31, 2015, includes cash-based amounts of approximately \$158,000 which consisted of \$24,000 in royalty-based financing fees payable on the promissory notes (including \$9,000 payable to a related party), \$1,000 interest on the repayable government contributions liability and \$133,000 in cash-based interest on the convertible debentures (including \$11,000 payable to a related party). The expense for the period also includes a non-cash-based amount of \$95,000 pertaining to the accretion of interest on the carrying value of the loan component of the convertible debt.

Interest and financing expense for the six months ended October 31, 2014, includes cash-based amounts of approximately \$111,000 which consisted of \$51,000 in interest and royalty-based financing fees payable on the promissory notes (including \$19,000 payable to a related party), \$2,000 interest on the repayable government contributions liability, \$57,000 in cash-based interest on the convertible debentures (including \$9,000 payable to a related party) and \$1,000 of fees on advances from related parties. The expense for the period also includes a non-cash-based amount of \$29,000 pertaining to the accretion of interest on the carrying value of the loan component of the convertible debt.

Net Income (Loss)

A net loss of \$980,000 was recorded for the first half of fiscal 2016, compared to a net loss of \$413,000 for the first half of fiscal 2015.

The net loss for the first half of fiscal 2016 includes the non-cash items of depreciation and amortization of approximately \$34,000 (fiscal 2015 – \$33,000), share-based compensation/consulting expenses of approximately \$70,000 (fiscal 2015 – \$63,000) and non-cash interest of \$95,000 (fiscal 2015 – \$29,000).

4. Selected Quarterly Financial Information

The following tables present selected quarterly financial information derived from the Company’s unaudited statements of operations and cash flows for the eight most recent quarters ended October 31, 2015. The comparative net loss per share figures have been adjusted to reflect the effect of the 10 to 1 share consolidation that was enacted in June of 2014. These operating results are not necessarily indicative of results to be achieved for any future period and should not be relied upon to predict future performance.

Selected Financial Information by Fiscal Quarter								
All items in \$ 000's, except Net (Loss) Income per Share								
Three months ended,	Oct. 31,	Jul. 31,	Apr. 30,	Jan. 31,	Oct. 31,	Jul. 31,	Apr. 30,	Jan. 31,
	2015	2015	2015	2015	2014	2014	2014	2014
Revenue	244	257	256	581	625	147	214	45
Plant operating expenses	351	330	302	439	364	135	254	214
Research and material testing expenses	1	2	2	2	2	2	2	2
SG&A expenses	267	274	319	253	343	212	301	244
Net (Loss) Income	(505)	(475)	(528)	(230)	(175)	(238)	(857)	(440)
Net Loss per Share	(0.03)	(0.03)	(0.04)	(0.02)	(0.01)	(0.02)	(0.06)	(0.03)
Operating Cash flow	(88)	(207)	(347)	(183)	(343)	(407)	(145)	(121)

5. Liquidity and Capital Resources

Sources and Uses of Cash

As at October 31, 2015 the Company had approximately \$8,000 of cash and cash equivalents on hand. For the first half of fiscal 2016, the cash flow used in operating activities was approximately \$295,000 (fiscal 2015 – used \$751,000). For first six months of fiscal 2016, cash utilized by operating activities was the result of a net loss adjusted for items not involving cash of approximately \$705,000 (fiscal 2015 - \$264,000) and cash provided by changes in non-cash working capital balances of \$410,000 (fiscal 2015 – cash used by changes in working capital \$487,000).

For the six month periods ended October 31, 2015, and October 31, 2014, there were no cash flows as the result of investing activities.

Financing activities in the six months ended October 31, 2015 were minimal. For the six months ended October 31, 2014, cash provided by financing activities was \$999,000 as the result of proceeds from the convertible debenture issuance (\$1,047,000), less repayment of government contributions (\$48,000).

Investments in Property, Plant and Equipment

There was no capital expenditure for the periods ended October 31, 2015 and 2014. Management maintains its capital expenditure with the goal of meeting expected production demands and with a reduced emphasis on investing in assets that are focused solely on R&D activities.

Licenses and technology rights

Cymat controls the following patent elements related to its SAF which cover:

- the fundamental process to make foam, irrespective of final shape;
- the fundamental process to make foam as a shaped part or a flat panel; and
- the fundamental process to make shaped parts using displacement casting.

Some of these patents are controlled under a license from Alcan International Inc. [“Alcan”]; some have been acquired from Hydro Aluminum a.s. [“Hydro”]; and Cymat has developed others independently. The scope of patent protection provides Cymat with important cost advantages in the production of aluminum foams.

Cymat continues to develop and protect its intellectual property and its proprietary manufacturing processes. It is Cymat's intention to continue to vigorously employ all legal remedies available to enforce its intellectual property rights.

Going Concern Uncertainty

To date, the Company has financed its operations primarily through share issuances, investment tax credits, interest income, and collaborative co-development agreements. The Company has incurred significant operating losses and cash outflows from operations. As at October 31, 2015, the anticipated level of cash flows from operating activities for the next twelve months is not assured to be sufficient to sustain operations. The ability of the Company to continue as a going concern is dependent upon raising additional financing through borrowings or equity financing and ultimately achieving future profitable operations. The outcome of these matters is dependent on a number of items outside the Company's control. As a result, there are material uncertainties that may cast significant doubt as to whether the Company will have the ability to continue as a going concern. The financial statements for the six months ended October 31, 2015 do not include any adjustments or disclosures that may result from the Corporation's inability to continue as a going concern. If the going concern assumption were not found to be appropriate for these financial statements, adjustments might be necessary in the carrying values of assets and liabilities, the statement of financial position classifications and the reported expenses. Such adjustments could be material.

6. Investments and Capitalization

Cymat is listed on the TSX – Venture Exchange, trading under the symbol CYM.

The table below sets out the number of issued and outstanding common shares, as well as the number of issued and outstanding convertible securities as at December 14, 2015.

	Number of Securities (Post Share Consolidation)
Common Shares	14,457,180
Convertible Debentures	11,956,250
Share Purchase Options	2,146,979
Warrants	<u>12,006,250</u>
Total Diluted Shares Outstanding	<u>40,566,659</u>

Share Capital

The Company is authorized to issue an unlimited number of common shares. At October 31, 2015, issued and outstanding common shares were approximately 14,457,180 common shares, on a post share consolidation basis.

In June of 2014, the Company enacted a Share Consolidation (the "Consolidation") whereby ten (10) pre-consolidation common shares were exchanged for one (1) post consolidation share. After the Consolidation, issued and outstanding common shares totalled approximately 14,407,180 shares. As a result of the Consolidation, the warrants and stock options that were outstanding at the time were also reduced in number by a factor of ten and their associated exercise prices were adjusted by a multiple of ten. The numbers of outstanding common shares reflected in these financial statements have been retroactively adjusted to give effect to the Consolidation. This adjustment affects the weighted average number of common shares and the associated loss per share calculations, among other share-related figures.

In January 2015, the Company issued 50,000 common shares as the result of the conversion of convertible debentures with a face value of \$10,000.

The Company has not paid dividends on its common shares and has no expectations of paying dividends in the near future.

Stock Options

The Company's stock option plan allows for the issuance of options, in aggregate, to acquire up to twenty percent (20%) of the number of common shares issued and outstanding on the effective date of the plan. The aggregate number of shares reserved for issuance under the terms of the Company's stock option plan is 2,881,437 on a post share consolidation basis.

The Company's stock option plan provides that the exercise price of options that may be granted cannot be less than the market price of the Company's common shares at the time the option is granted. Options granted may be exercised during a period not exceeding five years. The vesting period of plan options granted is at the discretion of the Company's Board of Directors at the time of grant.

During the six months ended October 31, 2015, options were granted as follows:

- On June 29, 2015, the Company granted 447,859 options to certain directors, officers and employees at an exercise price of \$0.125, with 34% vesting upon grant, 33% vesting on the first anniversary of the grant date and 33% vesting on the second anniversary of the grant date.

During the year ended April 30, 2015, options were granted as follows:

- On October 28, 2014, the Company granted 100,000 options to directors at an exercise price of \$0.185, with 34% vesting upon grant, 33% vesting on the first anniversary of the grant date and 33% vesting on the second anniversary of the grant date.
- On October 28, 2014, the Company granted 850,000 options to certain officers at an exercise price of \$0.185, with 34% vesting upon grant, 33% vesting at the end of fiscal 2016 and 33% vesting at the end of fiscal 2017. The final number of options to vest in fiscal 2016 and 2017 is dependent upon the attainment of certain performance criteria.

- On April 24, 2015, the Company granted 100,000 options to a consultant at an exercise price of \$0.13, with 25% vesting on July 24, 2015, 25% vesting on October 24, 2015, 25% vesting on January 24, 2015 and 25% vesting on April 24, 2016.

No options were exercised in the six months ended October 31, 2015, or in the year ended April 30, 2015.

7. Critical Accounting Policies and Estimates

Revenue recognition

Revenue from the sale of manufactured products is recognized when the rights and obligations associated with the products are transferred to the purchaser. Normally this transfer occurs upon the products' departure from the Company's warehouse; however based on the terms of the specific transaction, transfer can also occur upon the product arrival at a designated shipment location. Amounts received in advance of earned revenues are recorded as deferred revenue.

Convertible debentures

The convertible debentures are accounted for as a compound financial instrument that contains both a liability component, represented by the loan, and an equity component, represented by the share purchase warrants and conversion feature. The Company has allocated the total proceeds of the issuance between the debt and equity components of the convertible debenture using the residual method. First the fair value of the debt component was calculated as the present value of the related cash flows using an appropriate discount rate. The remaining proceeds were allocated to the equity components of the convertible debt with this amount divided between the warrants and the conversion feature based on their relative fair values as calculated using the Black-Scholes option pricing model. The fair value of the debt portion is accreted to its face value through the recording of interest expense, calculated using the effective rate method, over the term of the convertible debentures.

Use of estimates

The preparation of these financial statements in accordance with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual amounts could differ from those estimates. Significant estimates include those used in:

- the measurement of the cost of finished goods inventory, including the allocation of costs of conversion and manufacturing overhead,
- impairment of inventory,
- allowance for doubtful accounts,
- the determination of the useful lives of long lived assets,
- the determination of the appropriate amount, if any, of the writedown in the carrying value of long term assets, including the estimation of the associated future cash flows and the appropriate discount rate used to estimate the recoverable amount,
- the valuation of the accrued royalties on the promissory notes, including the forecasted revenues and the appropriate discount rate to apply in the determination of the present value,
- the valuation of repayable government contributions, including the timing of the future repayments and the appropriate discount rate to apply in the determination of present value, and
- the measurement of the fair value of share-based compensation, including the volatility and risk free rates used in the option valuation models and the estimation of number of options expected to vest.

Judgments

In the process of applying the Company's accounting policies, management has made judgments regarding the determination of whether there has been impairment in the carrying value of long term assets which has the most significant effect on the amounts recognized in the financial statements.

8. Accounting Standards Issued But Not Yet Applied

The IASB has issued a number of amendments to standards that are not yet effective for the fiscal year ending April 30, 2016. Accordingly these standards have not been applied by the Company in the preparation of these financial statements.

The following is a description of the new standards:

The IASB published IFRS 9 Financial Instruments which replaces IAS 39 Financial Instruments: Recognition and Measurement. IFRS 9 addresses the classification, measurement and derecognition of financial assets and financial liabilities, substantially overhauls accounting requirements related to hedging and introduces a new credit loss impairment model. The IASB also has a separate active project on accounting for macro hedging.

IFRS 9 will be effective for annual periods beginning on or after January 1, 2018. The Company does not anticipate early adoption of this standard and has not yet assessed its impact on the financial statements.

The IASB has published IFRS 15 Revenue from Contracts with Customers, the product of a major joint project between the IASB and the US Financial Accounting Standards Board. The previous requirements of IFRS and US GAAP were not harmonized and often resulted in different accounting treatments for economically similar transactions. In response, the Boards developed new, fully converged requirements for the recognition of revenue under both IFRS and US GAAP.

IFRS 15 replaces IAS 18 Revenue, IAS 11 Construction Contracts and some revenue-related Interpretations; establishes a new control-based revenue recognition model; changes the basis for deciding whether revenue is to be recognized over time or at a point in time; provides new and more detailed guidance on specific topics; and expands and improves disclosures about revenue.

IFRS 15 applies to contracts with customers to provide goods or services, including construction contracts and licensing of intellectual property. It will not apply to certain contracts within the scope of other IFRSs such as lease contracts, insurance contracts, financing arrangements, financial instruments, guarantees other than product warranties, and non-monetary exchanges between entities in the same line of business to facilitate sales to third-party customers.

IFRS 15 will be effective for annual periods beginning on or after January 1, 2018. The Company does not anticipate early adoption of this standard and has not yet assessed its impact on the financial statements.

9. Related Party Transactions

During the six months ended October 31, 2015, the Company received advances totaling \$Nil (year ended April 30, 2015 - \$14,500) from certain officers of the Company and repaid advances totaling \$Nil (year ended April 30, 2015 - \$14,500).

Interest and financing expense for the six month period ended October 31, 2015 includes financing fees totaling \$Nil (2014 - \$1,500) paid or payable to related parties with respect to advances. Interest and financing expense for the first half of fiscal 2016 also includes interest in the amount of \$Nil (2014- \$5,000) and royalties in the amount of \$9,000 (2014 - \$15,000) regarding promissory notes and interest expense in the amount of \$21,000 (2014 - \$9,000) regarding convertible debentures.

10. Risks and Uncertainties

Financial and Liquidity Risk

The Company has not yet attained sufficient sales levels to completely support its operations. As at October 31, 2015, the anticipated level of cash flow from operations for the next twelve months is not assured to be sufficient to sustain the business. In addition to being able to successfully execute its business plan, which includes increased sales, it may be necessary for the Company to raise additional financing through either borrowings or equity financing. There can be no assurance that the Company will succeed in growing sales sufficiently or in completing additional financing.

Dependence on Key Personnel

Cymat is dependent on key employees and believes that its future success will depend on its ability to attract and retain highly skilled engineering and production, managerial and marketing personnel. Competition for such personnel is intense and there is no assurance that the Company will be able to retain, attract or hire qualified personnel in the future. The loss of certain key employees, or the inability to hire and retain additional key employees could adversely impact the Company.

Proprietary Technology Protection

Cymat's technology leadership is subject to the risks of patent infringement by competitors, and of competitors making technological breakthroughs, which may make the Company's products less attractive. An intellectual property management program is in place to protect Cymat's intellectual property and trade secrets. Cymat funds ongoing improvements to its proprietary manufacturing processes, which create new patent opportunities that enhance and may extend the period of the technological exclusivity. There is the risk that the Company's patents and trade secrets may not be held valid and enforceable, or be held to have a scope sufficiently broad to cover competitors' products or processes. There is also the risk that Cymat's products or process may infringe on other patents, which may limit the Company's ability to fully commercialize certain SAF applications. The cost of enforcing Cymat's patent rights in lawsuits or defending against infringement claims may be significant and could interfere with the Company's operations. For a more complete discussion please refer to the "License and Technology Rights" section above.

Government Regulation and Certification Requirements Imposed by Customers

The use of SAF in certain applications may be subject to regulation by certain government bodies and to compliance with applicable laws, both inside and outside of Canada. In addition, industry users may

impose significant certification, safety, quality control and other requirements. Compliance with these laws and regulations may be costly and time consuming, and failure to comply may have a material, adverse effect on the Company's business.

Other Risks

The Company may be subject to a number of other risks that could materially and adversely affect Cymat's business, financial condition, liquidity or results of operations. Such risks include those associated with competing products, international markets and the possibilities of trade restrictions and the ability of the Company to manage growth.

11. Management's Assessment of Disclosure Controls and Procedures

Management is responsible for the design of internal controls over financial reporting to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements in accordance with accounting principles generally accepted in Canada. Overall, the Company believes its internal controls and procedures are effective in providing reasonable assurance that financial information is recorded, processed, summarized and reported in a timely manner.

Management is also responsible for the design and effectiveness of disclosure controls and procedures to provide reasonable assurance that material information related to the Company is made known to the Company's certifying officers.

There were no changes in the internal controls over financial reporting during the three month period ended October 31, 2015, that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting

12. Subsequent Event

In December 2015, the Company issued Convertible Debentures (the "Debentures") with a face value of \$463,000 through a non-brokered Private Placement Financing (the "Financing"). The Financing consisted of Debenture Units (the "Units") priced at \$1,000 per Unit with each Unit consisting of Debentures in the principal amount of \$1,000 and 5,000 Common Share Purchase Warrants (the "Warrants"). The Debentures bear interest at a rate of 12% per annum, mature on June 30, 2017, and are convertible, at the option of the holder, into 5,000 Common Shares. Each Warrant entitles the holder to purchase one Common Share at an exercise price of \$0.25 until June 30, 2017. A finder's fee in the amount of \$12,500 was payable in regards to the Financing.

13. Outlook

The bulk of the Caxia Forum AlusionTM order shipped after period end, generating revenue of approximately \$195,000. In addition to the orders announced in an October press release, Cymat has expectations for the inclusion of AlusionTM in significant architectural projects including installations located in the United States, Europe and in South America.

As recently announced, Cymat has received an initial order from Panhard General Defense for 250 SmartMetalTM blast mitigation kits to be installed on Panhard's light armoured 4X4 wheeled class of vehicles. This represents the Company's first serial-production military vehicle order. In addition to

Panhard, Cymat continues to be actively engaged with several Defense and Security industry manufacturers in the development of blast energy absorption systems for vehicles. Based on prototype and quoting activity in this segment, Cymat expects additional significant developments in SmartMetal™ blast mitigation applications.

Cymat also continues to explore non-vehicular energy absorption applications for SmartMetal™. As announced in November, Cymat has received an order for SmartMetal™ panels to be employed at the nuclear material facilities of the French Alternative Energies and Atomic Energy Commission (the “CEA”). The SmartMetal™ panels have been engineered for installation in the base of cargo lifts used in the transport of radioactive material and will act as a failsafe energy absorber as protection in the event of a major lift failure.

In the automotive sector, the Company is engaged in discussions concerning the development of SmartMetal™ applications on several fronts including noise, vibration and harshness (“NVH”) mitigation applications and a vehicle crash energy management system. Cymat management remains convinced that SmartMetal™ has the potential to resolve the conflicting requirements within automotive design for increased vehicle crashworthiness while at the same time reducing vehicle weight.